Evidence map›Paper›PMID 35089069›Full record

ArticlemBio2022

Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.

Shiwen Peng, Deyin Xing, Louise Ferrall, Ya-Chea Tsai, Richard B S Roden, Chien-Fu Hung, T-C Wu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shiwen PengDepartment of Pathology, The Johns Hopkins Universitygrid.471401.7grid.21107.35grid.471401.7grid.21107.35grid.471401.7, Baltimore, Maryland, USA.
Deyin XingDepartment of Pathology, The Johns Hopkins Universitygrid.471401.7grid.21107.35grid.471401.7grid.21107.35grid.471401.7, Baltimore, Maryland, USA.
Louise FerrallDepartment of Pathology, The Johns Hopkins Universitygrid.471401.7grid.21107.35grid.471401.7grid.21107.35grid.471401.7, Baltimore, Maryland, USA.
Ya-Chea TsaiDepartment of Pathology, The Johns Hopkins Universitygrid.471401.7grid.21107.35grid.471401.7grid.21107.35grid.471401.7, Baltimore, Maryland, USA.
Richard B S RodenDepartment of Pathology, The Johns Hopkins Universitygrid.471401.7grid.21107.35grid.471401.7grid.21107.35grid.471401.7, Baltimore, Maryland, USA.ORCID 0000-0002-2506-0195
Chien-Fu HungDepartment of Pathology, The Johns Hopkins Universitygrid.471401.7grid.21107.35grid.471401.7grid.21107.35grid.471401.7, Baltimore, Maryland, USA.
T-C WuDepartment of Pathology, The Johns Hopkins Universitygrid.471401.7grid.21107.35grid.471401.7grid.21107.35grid.471401.7, Baltimore, Maryland, USA.
Johns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer ImmunotherapyR01CA237067 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2019 to 2023
$2.9M
Development and Characterization of Immunotherapies for HPV-Associated MalignanciesR50CA251953 · NCI · JOHNS HOPKINS UNIVERSITY · PI PENG, SHIWEN · 2020 to 2024
$490k
Novel strategy combined with targeted radiation therapy unleashes potentantitumor immunity in HPV + head and neck cancerR21CA256020 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2021 to 2022
$417k
NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA237067NCI NIH HHS R21 CA256020NCI NIH HHS R50 CA251953
6 · The paper itself

Abstract

Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is a growing global health problem. HPV16 has been attributed to a majority of HPV-associated HNSCCs. In order to test candidate immunotherapies, we developed a spontaneous HPV16-driven HNSCC model in HLA-A2 (AAD) transgenic mice. We sought to eliminate the confounding effects of dominant HPV antigen presentation through murine major histocompatibility complex class I (MHC-I) via epitope mutagenesis (without compromising tumorigenicity). We generated HPV16 E6(R55K)(delK75) and E7(N53S) expression constructs with mutations in known dominant H-2D

Indexed as

Head and Neck NeoplasmsOncogene Proteins, ViralPapillomavirus InfectionsAnimalsCD8-Positive T-LymphocytesEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA-A2 AntigenHuman papillomavirus 16HumansMiceMice, Inbred C57BLMice, TransgenicPapillomavirus E7 ProteinsSquamous Cell Carcinoma of Head and NeckEpitopes, T-LymphocyteHistocompatibility Antigens Class IHLA-A2 AntigenOncogene Proteins, ViralPapillomavirus E7 ProteinsE6E7HPV16human papillomavirusOPSCCoral tumor model

Identifiers

PMID35089069
PMCPMC8725581
OpenAlexW4205431712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.